PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, and medical device sectors, has named Linda Matthews, President, BioCareSD, Inc., as one of the 2018 PM360 ELITE 100 in the Transformational Leader...
Blood Systems, Incorporated has announced that the operations of BioCare, its plasma and biological therapeutics sales division, will be transferred to BioCare, Inc., a separate, for-profit subsidiary of Blood Systems, effective January 1, 2017. Blood Systems...
Manufacturer Shire has named BioCare as the exclusive, national authorized distributor for CEPROTIN, a Protein C concentrate replacement therapy. It is indicated for the prevention and treatment of venous thrombosis and purpura fulminans for pediatric and adult...
BioCare is excited to announce that Octapharma’s NUWIQ is now available. Nuwiq is the first and only recombinant FVIII produced in human cells without chemical modification. It is indicated in children and adults with Hemophilia A for on-demand treatment &...
BioCare announced that it has been named by Bio Products Laboratory Limited (BPL) as a distributor for Coagadex (coagulation factor X, human). Product is available for shipment. Coagadex was approved by the U.S. Food and Drug Administration...
Blood Systems, the parent company of BioCareSD, has been selected by Arizona Business Magazine and BestCompaniesAZ as one of 40 winners of the 2015 Arizona’s Most Admired Companies Awards (MAC) and is featured in the September/October...
The USDSCSA (United States Drug Supply Chain Security Act) requires product and transaction information for all sales of prescription drug products sold by a distributor or manufacturer effective July 1, 2015. Manufacturers and distributors are required to provide the...
BioCare has been selected by Baxter as the exclusive, national authorized distributor for OBIZUR, the only recombinant porcine sequence factor VIII replacement treatment for acquired hemophilia A (AHA). OBIZUR was approved by the FDA for the...
